DMA
Actually, if would not have cost GSK much to move Relenza to the hovione device and would have overcame the difficult usage problem.
- Forums
- ASX - By Stock
- BTA
- research data sankyo tjw
research data sankyo tjw, page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online